EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification and biological evaluation of benzimidazole-based compounds as novel TGFβR1 inhibitors

Hui-Ju Tseng, Yi-Wen Wu, Yan-Ling Chen, Tony Eight Lin, Yu-Ting Fang-Chin, Yueh-Lin Wu, Tzu-Ying Sung, Shih-Chung Yen, Jui-Hua Hsieh, Kai-Cheng Hsu, Shiow-Lin Pan

Journal of Enzyme Inhibition and Medicinal Chemistry · 2026

DOI: 10.1080/14756366.2025.2600746 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Enzyme Inhibition and Medicinal Chemistry, 2026. Verfasst von Hui-Ju Tseng und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Benzimidazoles, Receptor, Transforming Growth Factor-beta Type I, Antineoplastic Agents, Protein Kinase Inhibitors. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, TMU Research Centre of Cancer Translational Medicine”, Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TGF-β promotes progression and metastasis in later stages of tumour development, and inhibitors targeting TGF-β or its receptor have faced clinical limitations due to toxicity and poor selectivity. This study aimed to identify novel TGFβR1 inhibitors by screening the ChemDiv database using a structure-based virtual screening approach. Among the top-ranked compounds, 3282-0487 showed the highest potency. Its analogues were further evaluated, leading to four potent TGFβR1 inhibitors with sub-micromolar IC50 values. Molecular docking confirmed favourable binding interactions, and structure-activity relationship analysis highlighted key structural features contributing to inhibitory activity. Among these, compound 3282-0486 demonstrated the lowest IC50 values against colorectal cancer cells, inducing apoptosis and dose-dependent anti-migration effects. Its efficacy was further supported by changes in downstream TGFβR1 signalling, including p-Smad2, EMT markers, and PARP1 cleavage. Additionally, compound 3282-0486 exhibited selectivity for TGFβR1. Overall, these findings support compound 3282-0486 as a promising TGFβR1 inhibitor with therapeutic potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzimidazolesReceptor, Transforming Growth Factor-beta Type IAntineoplastic AgentsProtein Kinase InhibitorsHumansStructure-Activity RelationshipMolecular StructureDose-Response Relationship, DrugDrug Screening Assays, AntitumorMolecular Docking SimulationCell ProliferationApoptosisCell Movement

Stichwörter der Autor:innen

TGF-βTGFβR1kinase selectivitystructure-based virtual screening

Substanzen

BenzimidazolesReceptor, Transforming Growth Factor-beta Type IAntineoplastic AgentsProtein Kinase InhibitorsTGFBR1 protein, humanbenzimidazole

Autor:innen und Institutionen

  • School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
  • Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
  • Division of Nephrology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
  • TMU Research Center of Urology and Kidney, Taipei Medical University, Taipei, Taiwan.
  • Division of Nephrology, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.

Förderung

  • National Science and Technology Council
  • TMU Research Centre of Cancer Translational Medicine”
  • Ministry of Education
  • Intramural Research Program of the NIH, National Institute of Environmental Health Sciences

Zitieren

APA

Tseng, H. J., Wu, Y. W., Chen, Y. L., Lin, T. E., Fang-Chin, Y. T., Wu, Y. L., Sung, T. Y., Yen, S. C., Hsieh, J. H., Hsu, K. C., & Pan, S. L. (2026). Identification and biological evaluation of benzimidazole-based compounds as novel TGFβR1 inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry. https://doi.org/10.1080/14756366.2025.2600746

Vancouver

Tseng HJ, Wu YW, Chen YL, Lin TE, Fang-Chin YT, Wu YL, et al. Identification and biological evaluation of benzimidazole-based compounds as novel TGFβR1 inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry. 2026. doi:10.1080/14756366.2025.2600746

BibTeX
@article{Tseng2026,
  author = {Tseng, Hui-Ju and Wu, Yi-Wen and Chen, Yan-Ling and Lin, Tony Eight and Fang-Chin, Yu-Ting and Wu, Yueh-Lin and Sung, Tzu-Ying and Yen, Shih-Chung and Hsieh, Jui-Hua and Hsu, Kai-Cheng and Pan, Shiow-Lin},
  title = {Identification and biological evaluation of benzimidazole-based compounds as novel TGFβR1 inhibitors},
  journal = {Journal of Enzyme Inhibition and Medicinal Chemistry},
  year = {2026},
  doi = {10.1080/14756366.2025.2600746}
}
Kostenlos starten →